MEDS VS ALRN Stock Comparison

Performance

MEDS
10/100

MEDS returned -41.09% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

ALRN
10/100

ALRN returned -54.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

MEDS
36/100

MEDS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

ALRN
50/100

ALRN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

MEDS
10/100

MEDS has missed earnings 9 times in the last 20 quarters.

ALRN
10/100

ALRN has missed earnings 9 times in the last 20 quarters.

Profit

MEDS
22/100

Out of the last 20 quarters, MEDS has had 6 profitable quarters and has increased their profits year over year on 2 of them.

ALRN
10/100

Out of the last 20 quarters, ALRN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MEDS
52/100

MEDS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

ALRN
59/100

ALRN has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.

Analyst Price Targets

MEDS

"Analyst Price Targets" not found for MEDS

ALRN
100/100

4 analysts offer 12-month price targets for ALRN. Together, they have an average target of 0, the most optimistic target put ALRN at 0 within 12-months and the most pessimistic has ALRN at 0.

All score calculations are broken down here to help you make more informed investing decisions

TRxADE HEALTH, Inc. Common Stock Summary

Nasdaq / MEDS

Healthcare

Medical - Pharmaceuticals

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Aileron Therapeutics, Inc. Common Stock Summary

Nasdaq / ALRN

Healthcare

Biotechnology

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Power up your portfolio